-
公开(公告)号:US20100160627A1
公开(公告)日:2010-06-24
申请号:US12359465
申请日:2009-01-26
IPC分类号: C07D267/02
CPC分类号: C07K5/06034 , A61K38/00 , C07D223/16 , C07D267/10 , C07D267/14 , C07D281/06 , C07D281/10 , C07D405/04 , C07D417/12 , C07D417/14 , C07K5/06026 , C07K5/06191
摘要: Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid β protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit γ secretase and thereby inhibit the production of amyloid β protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.
摘要翻译: 具有式(I)的药物组合物含有它们的化合物及其用于治疗与淀粉样蛋白相关的神经障碍的方法; 蛋白质生产和神经系统疾病如阿尔茨海默病。 这些化合物抑制γ分泌酶,从而抑制淀粉样蛋白的生成; 蛋白质,从而起到防止淀粉样蛋白质神经沉积的形成的作用。
-
公开(公告)号:US07858776B2
公开(公告)日:2010-12-28
申请号:US12359465
申请日:2009-01-26
IPC分类号: C07D223/16
CPC分类号: C07K5/06034 , A61K38/00 , C07D223/16 , C07D267/10 , C07D267/14 , C07D281/06 , C07D281/10 , C07D405/04 , C07D417/12 , C07D417/14 , C07K5/06026 , C07K5/06191
摘要: Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid β protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit γ secretase and thereby inhibit the production of amyloid β protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.
摘要翻译: 具有式(I)的药物组合物含有它们的化合物及其用于治疗与淀粉样蛋白相关的神经障碍的方法; 蛋白质生产和神经系统疾病如阿尔茨海默病。 这些化合物抑制γ分泌酶,从而抑制淀粉样蛋白的生成; 蛋白质,从而起到防止淀粉样蛋白质神经沉积的形成的作用。
-
公开(公告)号:US20080318943A1
公开(公告)日:2008-12-25
申请号:US12141190
申请日:2008-06-18
申请人: Hui-Fang Chang , Marc Chapdelaine , Bruce Thomas Dembofsky , Keith John Herzog , Carey Horchler , Richard Jon Schmiesing
发明人: Hui-Fang Chang , Marc Chapdelaine , Bruce Thomas Dembofsky , Keith John Herzog , Carey Horchler , Richard Jon Schmiesing
IPC分类号: A61K31/5377 , C07D471/04 , C07K14/705 , A61P25/28 , A61P25/18 , A61K31/437
CPC分类号: C07D471/04
摘要: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. These novel compounds provide a treatment or prophylaxis of anxiety disorders, schizophrenia, cognitive disorders, and/or mood disorders.
摘要翻译: 本发明涉及具有以下结构式I的新化合物及其药学上可接受的盐,互变异构体或体内可水解的前体,组合物及其使用方法,其中R1,R2,R3,R4,R5和R6定义于 规格。 这些新化合物提供治疗或预防焦虑症,精神分裂症,认知障碍和/或情绪障碍。
-
-